

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

 **HIGHTIDE**  
**HighTide Therapeutics, Inc.**

**君圣泰医药**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2511)**

**VOLUNTARY ANNOUNCEMENT  
BUSINESS UPDATE**

This announcement is made by HighTide Therapeutics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company is pleased to announced that the Group plans to expand its business presence (the “**Proposed Business Expansion**”) to cover Hebei Province, the People’s Republic of China (“**China**”).

Currently, the Group has offices and research and development centers in Shenzhen, Shanghai, Nanchang and Hong Kong. By expanding our business presence in Hebei Province, which may include the establishment of a new northern China operational base for collaboration planning, regulatory affairs management and/or raw material production facility, the Group aims to attract top-notch talents with strong academic background and industry experience in northern China for strengthening and diversifying the Group’s industry and regulatory resources and/or raw materials supply capabilities. The Proposed Business Expansion also aligns with the Group’s commitment to fostering strategic collaborations and partnerships in drug development, manufacturing and/or commercialization of its core product in China. The Company is of the view that the Proposed Business Expansion will enable the Group to leverage on the resources available in northern China.

As at the date of this announcement, the Group is conducting feasibility studies on the Proposed Business Expansion and actively communicating with local authorities and stakeholders on the implementation details in connection with the proposed establishment of business presence. The Company will make further announcement(s) in accordance with the applicable provisions under The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited as and when required.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**HighTide Therapeutics, Inc.**  
**Dr. LIU Liping**

*Executive Director and Chief Executive Officer*

Hong Kong, 19 January, 2024

*As at the date of this announcement, the Board comprises Dr. LIU Liping and Ms. YU Meng as executive Directors; Mr. LI Li, Dr. ZHU Xun, Mr. MA Lixiong and Mr. JIANG Feng as non-executive Directors; and Mr. TAN Bo, Dr. Jin LI and Mr. HUNG Tak Wai as independent non-executive Directors.*